salinipostin-a and Malaria

In this issue of Cell Chemical Biology, Yoo et al. (2020) use chemical proteomics to identify target proteins for the potent antimalarial natural product Salinipostin A. Polypharmacology from targeting multiple parasite serine hydrolases and lipases limits resistance to the compound, making this a promising new approach for treating malaria.

Topics: Animals; Antimalarials; Bridged Bicyclo Compounds, Heterocyclic; Diet, Fat-Restricted; Hydrolases; Lipid Metabolism; Malaria; Parasites; Serine

Despite significant advances in antimalarial chemotherapy over the past 30 years, development of resistance to frontline drugs remains a significant challenge that limits efforts to eradicate the disease. We now report the discovery of a new class of antimalarials, salinipostins A-K, with low nanomolar potencies and high selectivity indices against mammalian cells (salinipostin A: Plasmodium falciparum EC50 50 nM, HEK293T cytotoxicity EC50 > 50 μM). These compounds were isolated from a marine-derived Salinospora sp. bacterium and contain a bicyclic phosphotriester core structure, which is a rare motif among natural products. This scaffold differs significantly from the structures of known antimalarial compounds and represents a new lead structure for the development of therapeutic targets in malaria. Examination of the growth stage specificity of salinipostin A indicates that it exhibits growth stage-specific effects that differ from compounds that inhibit heme polymerization, while resistance selection experiments were unable to identify parasite populations that exhibited significant resistance against this compound class.

Topics: Animals; Antimalarials; Biological Products; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; HEK293 Cells; Humans; Malaria; Marine Biology; Plasmodium falciparum